In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Dynavax Technologies Corp (NASDAQ: DVAX) closed at $9.91 down -2.08% from its previous closing price of $10.12. In other words, the price has decreased by -$2.08 from its previous closing price. On the day, 2.33 million shares were traded. DVAX stock price reached its highest trading level at $10.29 during the session, while it also had its lowest trading level at $9.77.
Ratios:
For a deeper understanding of Dynavax Technologies Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.59. For the most recent quarter (mrq), Quick Ratio is recorded 6.01 and its Current Ratio is at 6.65. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Sell and sets its target price to $12 from $15 previously.
On February 01, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $20. On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.JMP Securities initiated its Mkt Outperform rating on September 27, 2022, with a $22 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 22 ’25 when Myers Scott Dunseth bought 3,800 shares for $10.82 per share. The transaction valued at 41,116 led to the insider holds 35,004 shares of the business.
Deep Track Biotechnology Maste sold 1,094,994 shares of DVAX for $12,077,784 on Aug 21 ’25. The 10% Owner now owns 16,696,492 shares after completing the transaction at $11.03 per share. On Aug 22 ’25, another insider, Deep Track Biotechnology Maste, who serves as the 10% Owner of the company, sold 970,143 shares for $10.59 each. As a result, the insider received 10,273,814 and left with 15,726,349 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1162115968 and an Enterprise Value of 837956736. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.67 while its Price-to-Book (P/B) ratio in mrq is 2.35. Its current Enterprise Value per Revenue stands at 2.65 whereas that against EBITDA is 64.978.
Stock Price History:
The Beta on a monthly basis for DVAX is 1.24, which has changed by -0.08747697 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, DVAX has reached a high of $14.63, while it has fallen to a 52-week low of $9.22. The 50-Day Moving Average of the stock is -6.57%, while the 200-Day Moving Average is calculated to be -15.76%.
Shares Statistics:
For the past three months, DVAX has traded an average of 1.66M shares per day and 2188120 over the past ten days. A total of 117.23M shares are outstanding, with a floating share count of 116.62M. Insiders hold about 0.55% of the company’s shares, while institutions hold 96.80% stake in the company. Shares short for DVAX as of 1755216000 were 13874793 with a Short Ratio of 8.35, compared to 1752537600 on 15157751. Therefore, it implies a Short% of Shares Outstanding of 13874793 and a Short% of Float of 17.819999.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Dynavax Technologies Corp (DVAX) in the stock market.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between -$0.5 and -$0.5 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is $0.35, with 2.0 analysts recommending between $0.45 and $0.25.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $94M this quarter.It ranges from a high estimate of $96.92M to a low estimate of $91M. As of the current estimate, Dynavax Technologies Corp’s year-ago sales were $80.63MFor the next quarter, 4 analysts are estimating revenue of $77.35M. There is a high estimate of $81.2M for the next quarter, whereas the lowest estimate is $75.29M.
A total of 4 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $337.8M, while the lowest revenue estimate was $330M, resulting in an average revenue estimate of $334.95M. In the same quarter a year ago, actual revenue was $277.25MBased on 4 analysts’ estimates, the company’s revenue will be $390.46M in the next fiscal year. The high estimate is $417.12M and the low estimate is $358.02M.
